naghiyev-shutterstock-com
Naghiyev / Shutterstock.com
5 May 2016Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Allergan received final approval on Monday, May 2, for its Abbreviated New Drug Application to market a generic of AstraZeneca’s Crestor (rosuvastatin) tablets.

Crestor is used to treat high cholesterol and to prevent cardiovascular disease.

Robert Stewart, Allergan's executive vice president, said: “This first-to-market launch demonstrates the talent of our generics team in developing, manufacturing and bringing to market high-quality, affordable versions of widely used medications like Crestor.

“This is expected to be the largest generic launch in 2016, benefiting patients and reducing cost for US health systems.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.
Americas
4 April 2016   The Federal Trade Commission has sued Endo Pharmaceuticals for allegedly violating competition laws by agreeing to so-called pay-for-delay settlements surrounding the launch of generic versions of two drugs.
Americas
5 May 2016   AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.

More on this story

Americas
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.
Americas
4 April 2016   The Federal Trade Commission has sued Endo Pharmaceuticals for allegedly violating competition laws by agreeing to so-called pay-for-delay settlements surrounding the launch of generic versions of two drugs.
Americas
5 May 2016   AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.

More on this story

Americas
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.
Americas
4 April 2016   The Federal Trade Commission has sued Endo Pharmaceuticals for allegedly violating competition laws by agreeing to so-called pay-for-delay settlements surrounding the launch of generic versions of two drugs.
Americas
5 May 2016   AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.